# MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

> **NCT00174369** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** PD-0325901

## Key facts

- **NCT ID:** NCT00174369
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Terminated \[See Detailed Description for Termination Reason.\]
- **Last updated:** 2009-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174369, "MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00174369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*